- Key facts & figures
- Sanofi share
- Analysts / Vara Consensus
- Reports & publications
- Results & presentations
- Corporate governance
Annual General Meetings
- Our publications
- Being a shareholder
- Becoming a shareholder
- Shareholders committee
- U.S. investors
- Regulated information in France
- Get to know Sanofi
- Working at Sanofi
- Our Expertise, your future
- Join Sanofi
- Being our partner
- Understanding science discovering
- Developing and marketing innovative solutions
- Manufacturing and supply
- Empowering Life
- Healthcare Solutions
- Our approach
- Improving access to healthcare
- Working together
- Ethics and transparency
- Preserving the environment
CSR is an integral part of Sanofi’s core business strategy. By building a pragmatic and innovative approach to meet today’s CSR challenges, it contributes to value creation and improving our business.
Our CSR Governance
The Sanofi Board considers issues related to the Company’s strategy, in line with its concern for the interests of shareholders and other stakeholders, and CSR issues.
A CSR Cross-functional strategy Committee (CCC) was set up in 2017 to identify projects or topics that need to be discussed at the Executive Committee level.
Our CSR Ambition
CSR is a key asset of our strategy and has always played a fundamental role within our business and our ability to deliver our strategic objectives. Our CSR agenda focuses on the four key areas which have the greatest significance to our activities and our stakeholders: Ethics and Transparency, Access to Healthcare for the Underserved, Engage with Communities, and Healthy Planet.
SRI (Socially Responsible Investing) funds represent 10.5% of Sanofi shareholders base as at Dec. 31 2016 (i.e. 107.5m shares). According to the benchmark performed by Nasdaq, this rate is higher than the Healthcare sector average.
Sanofi is included in the main non-financial rating indices, recognizing our CSR performance:
- Dow Jones Sustainability Index (DJSI) World (Bronze Class) and Europe: reference index in sustainable development
- FTSE4Good (Financial Times Stock Exchange)
- Access to Medicines Index (ATM)
- Stoxx® Global ESG Leaders indices.
In 2016, Sanofi was ranked among the top 3 CSR performers in the pharma sector by the rating agencies Oekom Research and MSCI and obtained the following CDP scores:
- CDP Climate Change Index: Score A – Level “Leadership”
- CDP Water Index: Score B – Level “Management”.
In 2016 Sanofi reached the UN Global Compact Advanced Level and received an attestation of external assessment following the peer review of our Communication on Progress: http://www.unglobalcompact.org
The information in this report offers an update on our implementation of the ten UNGC principles.
Read more in the 2016 Integrated Report
September 20, 2017
August 21, 2017